Review broad breast-cancer recurrence-context bands from tumor size, grade, nodal status, and receptor pattern in a simplified educational worksheet.
Breast cancer recurrence review is one part of pathology interpretation, especially when tumor size, grade, lymph node status, ER/PR/HER2 pattern, and Ki-67 need to be summarized in one place. This page brings those standard factors together so the broad context is easier to read as educational background.
This worksheet groups the case into broad 5-year and 10-year recurrence-context bands based on standard prognostic factors. It classifies the tumor into broad molecular subtypes (Luminal A, Luminal B, HER2-enriched, Triple Negative), computes a Nottingham Prognostic Index-like score, and shows where genomic assays are commonly referenced in the literature. Validated tools such as Oncotype DX, MammaPrint, PREDICT, and CTS5 add information that this worksheet does not reproduce.
This page should be used as background only. It does not replace validated prognostic models, full pathology review, or clinician interpretation.
This worksheet provides broad recurrence-context bands, subtype summary, and assay context that can help organize pathology factors before a clinical discussion. It is most useful as background only, not as a stand-alone prognosis tool.
Simplified composite risk model incorporating: - Tumor size (T stage contribution) - Histologic grade (Nottingham combined grade) - Lymph node status (0, 1-3, 4-9, 10+) - ER and HER2 receptor status - Ki-67 proliferation index - Age at diagnosis NPI-like Score = (0.2 × tumor size in cm) + grade (1-3) + lymph node score (1-3) Molecular subtype from ER/PR/HER2/Ki-67 combination
Result: 5-year recurrence band: 20-40% — Moderate-high worksheet context.
A 2.5 cm, grade 2, ER+/HER2- tumor with 1-3 positive nodes and intermediate Ki-67 falls in the Luminal B subtype. In this worksheet, that combination lands in a broader 20-40% band rather than an individualized recurrence forecast, which is why validated tools and full pathology review still matter.
This page combines familiar clinicopathologic factors such as tumor size, grade, nodal status, receptor pattern, and Ki-67 into one simplified recurrence worksheet. That can be useful for educational review, but it is still only a rough summary of a much more detailed pathology and outcomes discussion.
Broad subtype labels such as Luminal A, Luminal B, HER2-enriched, and Triple Negative reflect recurring patterns in receptor status and proliferation. They help explain why tumors with similar size can still behave differently, even before formal genomic testing is considered.
Validated recurrence tools and genomic assays incorporate data that this worksheet does not. That is why the output here should be read as background context only rather than as an individualized prognosis or a management answer.
Last updated:
This page uses a simplified clinicopathologic worksheet built from tumor size, grade, nodal status, ER/PR/HER2 pattern, Ki-67, and an NPI-like score to place a case into broad recurrence-context bands. It also maps receptor patterns into familiar subtype labels so the pathology profile can be summarized in one place.
It is not a replacement for validated prognostic platforms or genomic assays. Tools such as PREDICT, Oncotype DX, MammaPrint, CTS5, and full pathology review provide information that this worksheet does not reproduce.
Oncotype DX is a 21-gene assay that produces a recurrence score for selected ER+/HER2- breast cancers. This page does not calculate that score; it only notes that genomic assays are commonly part of recurrence-risk discussions in certain pathology profiles.
Luminal A usually refers to an ER-positive, HER2-negative, lower-proliferation pattern, while Luminal B generally refers to an ER-positive pattern with higher proliferation, lower PR expression, or HER2 positivity. This page uses receptor status and Ki-67 as a simplified approximation of those subtype groupings.
Triple-negative tumors are often higher grade and more proliferative, which is why recurrence risk is often concentrated in the earlier years after diagnosis. This page uses that broad pattern only as educational context.
Yes. ER-positive cancers can have meaningful recurrence risk beyond 5 years, which is why the 10-year band remains relevant on this worksheet. The actual late-recurrence picture is more nuanced than this simplified model can capture.
The NPI combines tumor size, lymph node status, and histologic grade: NPI = (0.2 × size in cm) + grade (1-3) + lymph node score (1-3). This page shows an NPI-like value as one more way to summarize the pathology profile.
No. This page is only a simplified educational worksheet. It does not replace genomic assay results, validated prognostic models, pathology review, or clinician interpretation.